Research Article

The Effects of L-Arginine on Liver Damage in Experimental Acute Cholestasis an Immunohistochemical Study

Yuçe l Ozsoy,1 Mustafa Ozsoy,1 Teoman Coskun,2 Kemal Namlı,3 Ahmet Var,4 and Beyhan Özyurt5

1 Department of General Surgery, Manisa State Hospital, Manisa, 35630 İzmir, Turkey
2 Department of General Surgery, School of Medicine, Celal Bayar University, 45000 Manisa, Turkey
3 Department of Immunopathology, School of Medicine, Celal Bayar University, 45000 Manisa, Turkey
4 Department of Biochemistry, School of Medicine, Celal Bayar University, 45000 Manisa, Turkey
5 Department of Public Health and Biostatistics, School of Medicine, Celal Bayar University, 45000 Manisa, Turkey

Correspondence should be addressed to Mustafa Ozsoy, dr.mustafaozsoy@gmail.com

Received 22 September 2010; Revised 3 April 2011; Accepted 13 April 2011

Academic Editor: Guntars Pupelis

Copyright © 2011 Yuçe l Ozsoy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Obstructive jaundice damages critical functions in the liver. Nitric oxide modulation would influence liver damage induced by biliary obstruction, and little is known about it. Acute cholestasis was induced by bile duct ligation (BDL) in two groups of male Sprague-Dawley rats. L-Arginine or serum physiologic was administered to treatment and control group. Histopathological and immunohistochemical iNOS expression was investigated in hepatic tissue. Plasma enzyme activities were increased in acute cholestasis, and that L-arginine treatment partially but significantly prevented the elevation of these markers of liver damage ($P < .05$). Also histopathology scoring showed that the liver injury was prevented and immunohistochemical iNOS activity was increased significantly in L-arginine group ($P < .05$). This study shows that, after 7 days of biliary obstruction, liver damage is well established and exogenous L-arginine treatment partially but significantly prevented the liver injury in acute cholestasis.

1. Introduction

Biliary obstruction is a common surgical problem. Despite the advances in diagnostic and therapeutic modalities, its morbidity and mortality are high. Cardiovascular dysfunction, peripheral vasoconstriction, renal insufficiency, gastrointestinal hemorrhage, coagulopathy, and sepsis are major complications that affect its morbidity and mortality [1]. According to experimental and clinical studies, these complications develop because of hypotension, immunosuppression, hepatic dysfunction, and high serum levels of toxic substances such as bile salts and endotoxin [1]. Nitric oxide (NO), which appears as an intercellular and intracellular messenger, has a role in liver damage. The synthesis of NO from L-arginine is known to exist in a number of cells, including endothelial cells, macrophages, cerebellar neurons, neutrophils, Kupffer cells, and hepatocytes [2]. Macrophages and hepatocytes produce much greater quantities of NO, which is not detectable until several hours after exposure to a specific inflammatory or septic stimulus [3]. Although the roles of NO in liver damage induced by ischemia reperfusion [4], alcohol [5], dimethylnitrosamine [6], and immunological [7] liver injury have been studied, the function of NO in liver damage induced by bile duct ligation in the rat has not been ascertained.

This study was undertaken to determine if an alteration in NO production caused by external L-arginine administration would influence the degree of hepatic damage induced by a seven-day biliary obstruction.

2. Material and Methods

2.1. Animals. Thirty male Sprague-Dawley rats weighting 200–250 g were housed under standard laboratory conditions and allowed free access to food and water. Institutional
Table 1: Comparison of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and γ-glutamyl transpeptidase levels in sham-operated, obstructive jaundice and L-arginine groups.

| Group                        | T. bilirubin (U/L) | D. bilirubin (U/L) | AST (U/L) | ALT (U/L) | ALP (U/L) | GGT (U/L) |
|------------------------------|--------------------|--------------------|-----------|-----------|-----------|-----------|
| Sham (saline)                | 0.27 ± 0.3         | 0.02 ± 0.01        | 131 ± 23  | 90 ± 36   | 224 ± 42  | 2 ± 2     |
| Obstructive jaundice (saline)| 10 ± 3.0           | 8.00 ± 2.00        | 763 ± 88  | 233 ± 74  | 533 ± 11  | 25 ± 11   |
| L-Arginine                   | 7 ± 2.0            | 6.00 ± 2.00        | 347 ± 22  | 141 ± 71  | 365 ± 9   | 15 ± 4    |

Data are shown as means ± S.E.M.; ten rats were used in each group.

aP < .05 Mann-Whitney U-test in comparison with sham (saline) group.
bP < .05 Mann-Whitney U-test in comparison with obstructive jaundice (saline) group.

guidelines for animal care were followed throughout the experimental study. The rats were anesthetized by intramuscular 50 mg/kg ketamine hydrochloride (Ketalar, Eczacibaşı, Turkey) and 5 mg/kg xylazine hydrochloride (Rompun %2, Bayer). Extra hepatic cholestasis was induced by double ligation and section of the common bile duct with a 4/0 silk suture. Three groups of rats (n = 10) were used. The animals of the first group were sham operated. In the second group, animals were bile duct ligatured (BDL) and received 1 mL % 0.9 NaCl twice a day intraperitoneally (i.p.). Animals in the third group were BDL and given i.p. administration of 1 mL 500 mg/kg L-arginine twice a day. All the animals were sacrificed on the seventh day under ether anesthesia. Blood was collected by cardiac puncture, and the liver was rapidly removed. Small liver sections from the same lobe of liver from each rat were fixed in 10% neutral formalin, which was used for hematoxylin-eosin staining for histological and immunohistochemical examination under light microscopy.

2.2. Serum Enzyme Activities and Bilirubin Determination. Serum was also obtained for determination of aspartate aminotransferase (AST), alanine aminotransferase (ALT) [8], alkaline phosphatase (ALP) [9], and γ-glutamyl transpeptidase (γGTP) [10, 11] activities. All of these markers, especially ALT, ALP, and γGTP, are indicators of liver damage. Bilirubin content (kit from Mega, Merk, Germany) was studied for signs of cholestasis.

2.3. Histopathology and Immunocytochemistry. Liver histopathology was evaluated to show the effect of NO on cholestatic liver injury. Immunohistochemical study was performed to explain the effect of exogenous L-arginine on hepatic inducible nitric oxide synthases (iNOS) expression. Histopathological studies were performed on 5-μm slides. Inducible nitric oxide synthase (iNOS) was determined immunohistochemically by a standardized streptavidin-biotin-peroxidase method on formaline-fixed paraffin-embedded liver tissue. A quantitative method was used for immunohistochemical evaluation; the staining score was obtained by calculating the number of iNOS-stained epithelial cells per 100 asinus under 40x light microscopy.

Histopathological evaluation was performed with a quantitative method. Ten different squares were used in each section to score the injury in the liver tissue. We used a modified scoring system for focal hepatic necrosis, as described by Orrego et al. [1], which takes into account necrosis, bile duct proliferation, and periportal leukocyte infiltration [12] (Tables 2 and 3), under 40x light microscopy (Olympus Bx40, Japan).

3. Results

All bilirubins increased progressively after bile duct obstruction and reached a plateau between three and seven days after surgery. Because of the cholestatic liver damage, plasma bilirubin levels and the activities of aspartate aminotransferase [8], alanine aminotransferase, alkaline phosphatase [9] and γ-glutamyl transpeptidase [10, 11] were all significantly higher in BDL rats than in sham-operated rats (P < .001, Table 1).

L-arginine administration partially but significantly prevented the elevation of plasma enzyme activities in bile duct-ligated rats (P < .05, Table 1).

Histopathological studies showed significant differences between obstructive jaundice and L-arginine groups in hematoxylin-eosin-(H-E)-stained sections. In the obstructive jaundice group, swelling and vacuolization in the cytoplasm of hepatocytes, loss of eosinophilic structures, and nucleolus proliferation were seen. Dilatation of sinusoids due to periportal, perisinusoidal, and polimorpho- and mononuclear leukocyte infiltration was noticeable. Focal hepatic necrosis and periportal new bile canaliculi proliferation were also observed (Figure 1). These findings were less evident in the L-arginine treatment group in which there was minimal periportal, perisinusoidal, polimorpho- and mononuclear leukocyte infiltration. There were also less piknotic nucleus cells and necrosis in the exogen L-arginine-administered group (Figure 2) and (Tables 2 and 3).

Immunohistochemical staining was evaluated in the hepatocytes using cytoplasmic patterns. In the sham-operated group, iNOS staining was almost absent in liver parenchyma and periportal areas (Figure 3). In the bile duct-ligated group, iNOS staining was most evident in necrotic areas, and observed to a lesser extent in liver parenchyma (Figure 4).

In the same areas in the obstructive jaundice + L-arginine group, iNOS staining intensity increased with L-arginine administration, and focal necrosis, bile duct proliferation, and periportal leukocyte infiltration were partially, but significantly, (P < .001) prevented (Figure 5).

The iNOS tissue staining scores were 15.85% in the sham-operated group, 32.70% in the BDL group, and 65.22% in the obstructive jaundice + L-arginine group; there were sig-
Figure 1: The liver histopathological changes in obstructive jaundice group, H-E ×40. Focal necrosis areas (a), bile duct proliferation (b) and periportal PMN leucocytes infiltration (c). CV: central vein. P: portal vein.

Table 2: Cholestatic liver injury scale.

| Necrosis                                      |         |
|-----------------------------------------------|---------|
| No necrosis                                   | (0 point) |
| Necrosis in one and/or two cells              | (1 point) |
| Focal necrosis that involves more than two cells | (2 point) |
| Massive confluent necrosis                    | (3 point) |
| Zonal massive necrosis and bridging necrosis between central veins | (4 point) |

| Bile duct proliferation                       |         |
|-----------------------------------------------|---------|
| 1-2 bile canaliculi proliferation             | (1 point) |
| 3-4 bile canaliculi proliferation             | (2 point) |
| >4 bile canaliculi proliferation              | (3 point) |

| Periportal leukocyte infiltration             |         |
|-----------------------------------------------|---------|
| Mild infiltration with one or two cells       | (1 point) |
| Moderate infiltration with more than two cells | (2 point) |
| Diffuse infiltration                          | (3 point) |

Table 3: Cholestatic liver injury score.

|                              | Obstructive jaundice group | L-arginine group |
|------------------------------|---------------------------|-----------------|
| Focal necrotic areas         | 2.11                      | 0.22*           |
| Ductus proliferation         | 2.7                       | 1.44*           |
| Periportal leukocyte infiltration | 2.4                   | 1.22*           |
| Total score                  | 7.2                       | 2.8*            |

*P < .001, Mann-Whitney U-test, in comparison with cholestatic (saline) group.

Figure 2: The liver histopathological changes in L-arginine group, H-E ×40. Less bile duct proliferation (b) and periportal PMN leucocytes infiltration (c) with no necrosis. CV: central vein. P: Portal vein.

Figure 3: Sham group was not dyed by iNOS. (iNOS ×40).

significant differences between the obstructive jaundice and L-arginine groups.

4. Discussion

In this work, we have studied the effects of exogenous L-arginine on the production of NO by regulating the expression of iNOS proteins. We have also studied the effect of exogenous arginine on cholestatic liver injury. Recent observations provide evidence that NO plays an important role in liver disease, but little is known about the role of arginine-iNOS pathways in cholestatic liver injury [3, 13]. Bile duct ligation in the rat is a good model to study drugs that might prevent or reverse liver injury [3]. In this study’s experiments, we have shown that, after seven days of biliary obstruction, liver damage was well established and is accompanied by decreased production of iNOS protein and elevated liver enzymes. As a consequence of the decrease in iNOS synthesis, liver blood supply and perfusion decreased. Ischemia and necrosis were observed in the liver under light microscopy [14].

Recent researches about the role of NO in the regulation of hepatic microcirculation have shown that the L-arginine-derived iNOS activation supports vasodilatation and inhibition of platelet functions. NO may exhibit its protective effects against liver injury through vasodilatation and inhibition of platelet and macrophage activities [15, 16]. In addition, studies in cholestatic rats have shown an association with hepatic ischemia because of the deficient production of iNOS and protein. This supports the hypothesis that NO regulates blood flow in cholestatic rats [17, 18].
Our study showed that histopathological changes, such as focal necrosis, new bile canaliculi proliferation, and periportal leukocyte infiltration, were partially but significantly prevented by exogenous L-arginine in obstructive jaundiced rats. L-arginine played a protective role by inducing iNOS expression and NO synthesis, and this is also shown histopathologically and immunohistochemically for the first time.

Muriel and González [3] and [23] have shown the effects of exogenous L-arginine in BDL rats with liver enzymes with markers of liver damage. Muriel suggested that L-arginine-induced NO production plays a protective role in cholestatic liver injury induced by 3-day biliary obstruction and showed this through decreased liver enzyme levels and lipid peroxidation, but further studies are needed to show the protective effects of exogenous L-arginine with histopathological findings and specific markers of liver injury [23]. The current experimental study has demonstrated that exogenous L-arginine partially but significantly decreases the liver enzyme levels and histopathological liver injury.

In summary, the present study suggests that L-arginine treatment partially but significantly prevents the liver injury in acute cholestasis by stimulation of iNOS expression and NO synthesis. This is shown histopathologically and immunohistochemically for the first time.

References

[1] H. Orrego, F. J. Carmichael, and M. J. Phillips, “Protection by propylthiouracil against carbon tetrachloride induced liver damage,” *Gastroenterology*, vol. 71, no. 5, pp. 821–826, 1976.

[2] L. Cantoni, F. Di Nicolantonio, D. Barelli, M. Rizzardini, and F. De Matteis, “Modulation of cerebellar and hepatic nitric oxide synthase by exogenous arginine and endotoxin,” *Nitric Oxide*, vol. 5, no. 2, pp. 198–207, 2001.

[3] P. Muriel and P. González, “Liver damage induced by acute cholestasis in the rat is ameliorated partially by L-arginine,” *Comparative Biochemistry and Physiology*, vol. 120, no. 3, pp. 421–424, 1998.

[4] C. Peralta, G. Hotter, D. Closa, E. Gelpi, O. Bulbena, and J. Roselló-Catafau, “Protective effect of preconditioning on the injury associated to hepatic ischemia-reperfusion in the rat: role of nitric oxide and adenosine,” *Hepatology*, vol. 25, no. 4, pp. 934–937, 1997.

[5] A. A. Nanji, S. S. Greenberg, S. R. Tahan et al., “Nitric oxide production in experimental alcoholic liver disease in the rat: role in protection from injury,” *Gastroenterology*, vol. 109, no. 3, pp. 899–907, 1995.

[6] S. Nagase, H. Isobe, K. Ayukawa, H. Sakai, and H. Nawata, “Inhibition of nitric oxide production increases dimethylnitrosamine-induced liver injury in rats,” *Journal of Hepatology*, vol. 23, no. 5, pp. 601–604, 1995.

[7] G. S. Wang and G. T. Liu, “Role of nitric oxide in immunological liver damage in mice,” *Biochemical Pharmacology*, vol. 49, no. 9, pp. 1277–1281, 1995.

[8] S. Reitman and S. Frankel, “A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases,” *American Journal of Clinical Pathology*, vol. 28, no. 1, pp. 56–63, 1957.

[9] H. U. Bergmeyer, M. Grabl, and H. E. Walter, *Methods of Enzymatic Analysis*, Verlag Chemie, Weinheim, Germany, 1983.
[10] M. Glossman and D. M. Neville, “Glutamyl transferase in kidney brush border membranes,” *The FEBS Letters*, vol. 19, pp. 340–344, 1972.

[11] M. Glossman and D. M. Neville, “Glutamyl transferase in kidney brush border membranes,” *Comparative Biochemistry and Physiology*, vol. 127, pp. 243–249, 2000.

[12] H. Zimmermann, J. Reichen, A. Zimmermann, H. Sagesser, B. Thenisch, and F. Hoflin, “Reversibility of secondary biliary fibrosis by biliodigestive anastomosis in the rat,” *Gastroenterology*, vol. 103, no. 2, pp. 579–589, 1992.

[13] H. Zimmermann, P. Kurzen, W. Klossner, E. L. Renner, and U. Marti, “Decreased constitutive hepatic nitric oxide synthase expression in secondary biliary fibrosis and its changes after Roux-en-Y choledocho-jejunostomy in the rat,” *Journal of Hepatology*, vol. 25, no. 4, pp. 567–573, 1996.

[14] H. Kanda, Y. Nimura, A. Yasui et al., “Hepatic blood flow after acute biliary obstruction and drainage in conscious dogs,” *Hepato-Gastroenterology*, vol. 43, no. 7, pp. 235–240, 1996.

[15] C. Bauer, F. Walcher, V. Kalveit et al., “Role of nitric oxide in the regulation of the hepatic microcirculation in vivo,” *Journal of Hepatology*, vol. 27, pp. 1089–1059, 1997.

[16] M. Suematsu, T. Tamatani, F. A. Delano et al., “Microvascular oxidative stress preceding leukocyte activation elicited by in vivo nitric oxide suppression,” *American Journal of Physiology*, vol. 266, no. 6, pp. H2410–H2415, 1994.

[17] V. Baron, J. Hernandez, M. Noyola et al., “Nitric oxide and inducible nitric oxide synthase expression are down regulated in acute cholestasis in the rat accompanied by liver ischemia,” *Comparative Biochemistry and Physiology*, vol. 127, pp. 243–249, 2000.

[18] P. Muriel, “Regulation of nitric oxide synthesis in the liver,” *Journal of Applied Toxicology*, vol. 20, no. 3, pp. 189–195, 2000.

[19] A. Nahavandi, A. R. Dehpour, A. R. Mani, H. Homayounfar, and A. Abdoli, "N(G)-nitro-L-Arginine methylester is protective against ethanol-induced gastric damage in cholestatic rats," *European Journal of Pharmacology*, vol. 370, no. 3, pp. 283–286, 1999.

[20] C. C. Chang, C. C. McCormick, A. W. Lin, R. R. Dietert, and Y. J. Sung, “Inhibition of nitric oxide synthase gene expression in vivo and in vitro by repeated doses of endotoxin,” *American Journal of Physiology*, vol. 271, no. 4, pp. G539–G548, 1996.

[21] M. Fernández, J. C. García-Pagán, M. Casadevall et al., “Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats,” *Gastroenterology*, vol. 108, no. 5, pp. 1487–1495, 1995.

[22] P. B. Soeters, M. M. Hallemeech, M. J. Bruins, H. M. H. Van Eijk, and N. E. P. Deutz, “Quantitative in vivo assessment of arginine utilization and nitric oxide production in endotoxemia,” *American Journal of Surgery*, vol. 183, no. 4, pp. 480–488, 2002.

[23] A. Nahavandi, A. R. Dehpour, A. R. Mani, H. Homayounfar, A. Abdoli, and M. R. Abdolhoseini, “The role of nitric oxide in bradycardia of rats with obstructive cholestasis,” *European Journal of Pharmacology*, vol. 411, no. 1-2, pp. 135–141, 2001.